TY - JOUR
T1 - Investigational drugs in development to prevent neuromyelitis optica relapses
AU - Paul, Friedemann
AU - Murphy, Olwen
AU - Pardo, Santiago
AU - Levy, Michael
N1 - Publisher Copyright:
© 2018 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2018/3/4
Y1 - 2018/3/4
N2 - Introduction: In the short time since 2014, three pivotal, worldwide studies in neuromyelitis optica spectrum disorders have been launched: eculizumab, SA237 and inebelizumab, each based on a unique mechanism. Areas covered: In this review, we provide a discussion on the trial data available for each drug, a brief description of the trial design, and our expert opinion on the potential benefits and risks. Expert opinion: Eculizumab, a C5 complement inhibitor, may prove useful in the treatment of intractable cases of NMOSD, but physicians must be aware of the known risk of meningococcal infection. SA237, an interleukin-6 receptor blocker, may be effective at reducing relapse risk, and also has the potential to reduce neuropathic pain in NMOSD. Inebelizumab, a B cell depleting agent, has never been tested in NMOSD, but based on extensive evidence of efficacy with B cell depletion using rituximab, inebelizumab is expected to work at least as well.
AB - Introduction: In the short time since 2014, three pivotal, worldwide studies in neuromyelitis optica spectrum disorders have been launched: eculizumab, SA237 and inebelizumab, each based on a unique mechanism. Areas covered: In this review, we provide a discussion on the trial data available for each drug, a brief description of the trial design, and our expert opinion on the potential benefits and risks. Expert opinion: Eculizumab, a C5 complement inhibitor, may prove useful in the treatment of intractable cases of NMOSD, but physicians must be aware of the known risk of meningococcal infection. SA237, an interleukin-6 receptor blocker, may be effective at reducing relapse risk, and also has the potential to reduce neuropathic pain in NMOSD. Inebelizumab, a B cell depleting agent, has never been tested in NMOSD, but based on extensive evidence of efficacy with B cell depletion using rituximab, inebelizumab is expected to work at least as well.
KW - Neuromyelitis optica
KW - biomarkers
KW - prognosis
KW - risk assessment
UR - http://www.scopus.com/inward/record.url?scp=85043602609&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043602609&partnerID=8YFLogxK
U2 - 10.1080/13543784.2018.1443077
DO - 10.1080/13543784.2018.1443077
M3 - Review article
C2 - 29465257
AN - SCOPUS:85043602609
SN - 1354-3784
VL - 27
SP - 265
EP - 271
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
IS - 3
ER -